nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—EGFR—urinary bladder cancer	0.372	1	CbGaD
Gefitinib—ABCB1—Mitomycin—urinary bladder cancer	0.0358	0.132	CbGbCtD
Gefitinib—ABCG2—Fluorouracil—urinary bladder cancer	0.0245	0.0903	CbGbCtD
Gefitinib—ABCG2—Carboplatin—urinary bladder cancer	0.0243	0.0897	CbGbCtD
Gefitinib—ABCG2—Cisplatin—urinary bladder cancer	0.0208	0.0767	CbGbCtD
Gefitinib—ABCG2—Etoposide—urinary bladder cancer	0.0204	0.0753	CbGbCtD
Gefitinib—ALB—Fluorouracil—urinary bladder cancer	0.0169	0.0622	CbGbCtD
Gefitinib—CYP3A4—Thiotepa—urinary bladder cancer	0.0163	0.06	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—urinary bladder cancer	0.0139	0.0514	CbGbCtD
Gefitinib—ABCG2—Methotrexate—urinary bladder cancer	0.0135	0.0498	CbGbCtD
Gefitinib—CYP3A5—Etoposide—urinary bladder cancer	0.0113	0.0417	CbGbCtD
Gefitinib—ABCB1—Gemcitabine—urinary bladder cancer	0.0103	0.0381	CbGbCtD
Gefitinib—ALB—Methotrexate—urinary bladder cancer	0.0093	0.0343	CbGbCtD
Gefitinib—CYP2C9—Fluorouracil—urinary bladder cancer	0.00909	0.0335	CbGbCtD
Gefitinib—CYP2C9—Cisplatin—urinary bladder cancer	0.00772	0.0285	CbGbCtD
Gefitinib—ABCB1—Cisplatin—urinary bladder cancer	0.00749	0.0277	CbGbCtD
Gefitinib—ABCB1—Etoposide—urinary bladder cancer	0.00736	0.0272	CbGbCtD
Gefitinib—ABCB1—Doxorubicin—urinary bladder cancer	0.00502	0.0185	CbGbCtD
Gefitinib—ABCB1—Methotrexate—urinary bladder cancer	0.00486	0.018	CbGbCtD
Gefitinib—CYP2D6—Doxorubicin—urinary bladder cancer	0.00473	0.0175	CbGbCtD
Gefitinib—CYP3A4—Etoposide—urinary bladder cancer	0.00441	0.0163	CbGbCtD
Gefitinib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00301	0.0111	CbGbCtD
Gefitinib—CHEK2—prostate gland—urinary bladder cancer	0.00283	0.0364	CbGeAlD
Gefitinib—EPHA6—prostate gland—urinary bladder cancer	0.00254	0.0327	CbGeAlD
Gefitinib—CYP2C19—urine—urinary bladder cancer	0.00191	0.0246	CbGeAlD
Gefitinib—Lapatinib—ERBB2—urinary bladder cancer	0.0019	0.285	CrCbGaD
Gefitinib—EGFR—prostate gland—urinary bladder cancer	0.00187	0.024	CbGeAlD
Gefitinib—CSNK1E—prostate gland—urinary bladder cancer	0.0018	0.0231	CbGeAlD
Gefitinib—IRAK4—prostate gland—urinary bladder cancer	0.00177	0.0227	CbGeAlD
Gefitinib—HIPK4—female reproductive system—urinary bladder cancer	0.00175	0.0226	CbGeAlD
Gefitinib—ERBB3—prostate gland—urinary bladder cancer	0.00173	0.0223	CbGeAlD
Gefitinib—MKNK2—prostate gland—urinary bladder cancer	0.00165	0.0212	CbGeAlD
Gefitinib—IRAK1—prostate gland—urinary bladder cancer	0.00165	0.0212	CbGeAlD
Gefitinib—MKNK1—prostate gland—urinary bladder cancer	0.00163	0.0209	CbGeAlD
Gefitinib—CSNK1E—seminal vesicle—urinary bladder cancer	0.00152	0.0195	CbGeAlD
Gefitinib—IRAK4—seminal vesicle—urinary bladder cancer	0.0015	0.0192	CbGeAlD
Gefitinib—CYP2C9—urine—urinary bladder cancer	0.00148	0.0191	CbGeAlD
Gefitinib—CHEK2—vagina—urinary bladder cancer	0.0014	0.018	CbGeAlD
Gefitinib—MKNK2—seminal vesicle—urinary bladder cancer	0.00139	0.0179	CbGeAlD
Gefitinib—EPHA6—female reproductive system—urinary bladder cancer	0.00139	0.0178	CbGeAlD
Gefitinib—Afatinib—ERBB2—urinary bladder cancer	0.00135	0.202	CrCbGaD
Gefitinib—STK10—prostate gland—urinary bladder cancer	0.00134	0.0172	CbGeAlD
Gefitinib—ERBB3—epithelium—urinary bladder cancer	0.00127	0.0164	CbGeAlD
Gefitinib—MAP3K19—female reproductive system—urinary bladder cancer	0.00126	0.0162	CbGeAlD
Gefitinib—MKNK2—epithelium—urinary bladder cancer	0.00121	0.0156	CbGeAlD
Gefitinib—CSNK1E—urethra—urinary bladder cancer	0.0012	0.0155	CbGeAlD
Gefitinib—MAP2K5—prostate gland—urinary bladder cancer	0.0012	0.0154	CbGeAlD
Gefitinib—IRAK4—urethra—urinary bladder cancer	0.00118	0.0152	CbGeAlD
Gefitinib—ERBB3—renal system—urinary bladder cancer	0.00118	0.0152	CbGeAlD
Gefitinib—MKNK2—smooth muscle tissue—urinary bladder cancer	0.00117	0.015	CbGeAlD
Gefitinib—IRAK1—smooth muscle tissue—urinary bladder cancer	0.00117	0.015	CbGeAlD
Gefitinib—CYP3A4—urine—urinary bladder cancer	0.00113	0.0145	CbGeAlD
Gefitinib—MKNK2—renal system—urinary bladder cancer	0.00112	0.0144	CbGeAlD
Gefitinib—CYP2D6—urine—urinary bladder cancer	0.00111	0.0143	CbGeAlD
Gefitinib—MKNK2—urethra—urinary bladder cancer	0.0011	0.0142	CbGeAlD
Gefitinib—MKNK1—urethra—urinary bladder cancer	0.00109	0.014	CbGeAlD
Gefitinib—SBK1—lymph node—urinary bladder cancer	0.00104	0.0134	CbGeAlD
Gefitinib—MAP2K5—seminal vesicle—urinary bladder cancer	0.00101	0.013	CbGeAlD
Gefitinib—CSNK1E—female reproductive system—urinary bladder cancer	0.00098	0.0126	CbGeAlD
Gefitinib—ORM1—prostate gland—urinary bladder cancer	0.000971	0.0125	CbGeAlD
Gefitinib—ERBB3—female reproductive system—urinary bladder cancer	0.000946	0.0122	CbGeAlD
Gefitinib—STK10—renal system—urinary bladder cancer	0.000913	0.0117	CbGeAlD
Gefitinib—CHEK2—lymph node—urinary bladder cancer	0.000904	0.0116	CbGeAlD
Gefitinib—MKNK2—female reproductive system—urinary bladder cancer	0.000899	0.0116	CbGeAlD
Gefitinib—IRAK1—female reproductive system—urinary bladder cancer	0.000899	0.0116	CbGeAlD
Gefitinib—Lapatinib—EGFR—urinary bladder cancer	0.000899	0.135	CrCbGaD
Gefitinib—MKNK1—female reproductive system—urinary bladder cancer	0.000888	0.0114	CbGeAlD
Gefitinib—CSNK1E—vagina—urinary bladder cancer	0.000886	0.0114	CbGeAlD
Gefitinib—IRAK4—vagina—urinary bladder cancer	0.000873	0.0112	CbGeAlD
Gefitinib—MKNK2—vagina—urinary bladder cancer	0.000813	0.0105	CbGeAlD
Gefitinib—MKNK1—vagina—urinary bladder cancer	0.000803	0.0103	CbGeAlD
Gefitinib—MAP2K5—urethra—urinary bladder cancer	0.000801	0.0103	CbGeAlD
Gefitinib—CHEK2—Doxorubicin—Valrubicin—urinary bladder cancer	0.00075	0.2	CbGdCrCtD
Gefitinib—CHEK2—Epirubicin—Valrubicin—urinary bladder cancer	0.00075	0.2	CbGdCrCtD
Gefitinib—ERBB3—Podofilox—Etoposide—urinary bladder cancer	0.000741	0.198	CbGdCrCtD
Gefitinib—STK10—female reproductive system—urinary bladder cancer	0.000731	0.00941	CbGeAlD
Gefitinib—STK10—vagina—urinary bladder cancer	0.000661	0.00851	CbGeAlD
Gefitinib—MAP2K5—female reproductive system—urinary bladder cancer	0.000653	0.0084	CbGeAlD
Gefitinib—Afatinib—EGFR—urinary bladder cancer	0.000637	0.0956	CrCbGaD
Gefitinib—EGFR—lymph node—urinary bladder cancer	0.000596	0.00767	CbGeAlD
Gefitinib—MAP2K5—vagina—urinary bladder cancer	0.000591	0.0076	CbGeAlD
Gefitinib—ABCG2—prostate gland—urinary bladder cancer	0.000582	0.00749	CbGeAlD
Gefitinib—CSNK1E—lymph node—urinary bladder cancer	0.000573	0.00738	CbGeAlD
Gefitinib—IRAK4—lymph node—urinary bladder cancer	0.000564	0.00726	CbGeAlD
Gefitinib—ERBB3—lymph node—urinary bladder cancer	0.000553	0.00712	CbGeAlD
Gefitinib—CYP3A5—prostate gland—urinary bladder cancer	0.00054	0.00695	CbGeAlD
Gefitinib—ORM1—female reproductive system—urinary bladder cancer	0.00053	0.00682	CbGeAlD
Gefitinib—MKNK2—lymph node—urinary bladder cancer	0.000526	0.00677	CbGeAlD
Gefitinib—IRAK1—lymph node—urinary bladder cancer	0.000526	0.00677	CbGeAlD
Gefitinib—MKNK1—lymph node—urinary bladder cancer	0.000519	0.00668	CbGeAlD
Gefitinib—CHEK2—Teniposide—Etoposide—urinary bladder cancer	0.0005	0.134	CbGdCrCtD
Gefitinib—CHEK2—Podofilox—Etoposide—urinary bladder cancer	0.0005	0.134	CbGdCrCtD
Gefitinib—ABCG2—seminal vesicle—urinary bladder cancer	0.000492	0.00633	CbGeAlD
Gefitinib—Erlotinib—EGFR—urinary bladder cancer	0.00045	0.0676	CrCbGaD
Gefitinib—Vandetanib—SRC—urinary bladder cancer	0.000441	0.0662	CrCbGaD
Gefitinib—STK10—lymph node—urinary bladder cancer	0.000428	0.0055	CbGeAlD
Gefitinib—Bosutinib—SRC—urinary bladder cancer	0.000413	0.0619	CrCbGaD
Gefitinib—CYP1A1—epithelium—urinary bladder cancer	0.000406	0.00522	CbGeAlD
Gefitinib—ABCG2—urethra—urinary bladder cancer	0.00039	0.00501	CbGeAlD
Gefitinib—MAP2K5—lymph node—urinary bladder cancer	0.000382	0.00491	CbGeAlD
Gefitinib—CYP1A1—renal system—urinary bladder cancer	0.000377	0.00484	CbGeAlD
Gefitinib—CYP1A1—urethra—urinary bladder cancer	0.00037	0.00476	CbGeAlD
Gefitinib—CYP3A5—renal system—urinary bladder cancer	0.000368	0.00474	CbGeAlD
Gefitinib—CYP2C19—vagina—urinary bladder cancer	0.000339	0.00436	CbGeAlD
Gefitinib—ORM1—lymph node—urinary bladder cancer	0.00031	0.00399	CbGeAlD
Gefitinib—CYP1A1—female reproductive system—urinary bladder cancer	0.000302	0.00388	CbGeAlD
Gefitinib—Vandetanib—EGFR—urinary bladder cancer	0.000296	0.0445	CrCbGaD
Gefitinib—CYP2C9—female reproductive system—urinary bladder cancer	0.00029	0.00373	CbGeAlD
Gefitinib—ABCG2—vagina—urinary bladder cancer	0.000287	0.0037	CbGeAlD
Gefitinib—ABCB1—prostate gland—urinary bladder cancer	0.000287	0.00369	CbGeAlD
Gefitinib—Bosutinib—EGFR—urinary bladder cancer	0.000277	0.0416	CrCbGaD
Gefitinib—CYP3A4—renal system—urinary bladder cancer	0.000276	0.00356	CbGeAlD
Gefitinib—CYP1A1—vagina—urinary bladder cancer	0.000273	0.00351	CbGeAlD
Gefitinib—ALB—lymph node—urinary bladder cancer	0.000272	0.0035	CbGeAlD
Gefitinib—CYP2D6—renal system—urinary bladder cancer	0.000272	0.0035	CbGeAlD
Gefitinib—CYP3A5—vagina—urinary bladder cancer	0.000267	0.00343	CbGeAlD
Gefitinib—CHEK2—Doxorubicin—Epirubicin—urinary bladder cancer	0.000261	0.0697	CbGdCrCtD
Gefitinib—ABCB1—seminal vesicle—urinary bladder cancer	0.000243	0.00312	CbGeAlD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—urinary bladder cancer	0.000241	0.0645	CbGdCrCtD
Gefitinib—CYP3A4—female reproductive system—urinary bladder cancer	0.000221	0.00285	CbGeAlD
Gefitinib—CYP2D6—female reproductive system—urinary bladder cancer	0.000218	0.0028	CbGeAlD
Gefitinib—ABCB1—epithelium—urinary bladder cancer	0.000211	0.00271	CbGeAlD
Gefitinib—ABCB1—renal system—urinary bladder cancer	0.000196	0.00252	CbGeAlD
Gefitinib—ABCB1—urethra—urinary bladder cancer	0.000192	0.00247	CbGeAlD
Gefitinib—ABCG2—lymph node—urinary bladder cancer	0.000186	0.00239	CbGeAlD
Gefitinib—CYP1A1—lymph node—urinary bladder cancer	0.000176	0.00227	CbGeAlD
Gefitinib—ABCB1—female reproductive system—urinary bladder cancer	0.000157	0.00202	CbGeAlD
Gefitinib—Infection—Cisplatin—urinary bladder cancer	0.000144	0.00107	CcSEcCtD
Gefitinib—Hypotension—Fluorouracil—urinary bladder cancer	0.000143	0.00106	CcSEcCtD
Gefitinib—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000142	0.00105	CcSEcCtD
Gefitinib—Cough—Etoposide—urinary bladder cancer	0.000142	0.00105	CcSEcCtD
Gefitinib—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000142	0.00105	CcSEcCtD
Gefitinib—ABCB1—vagina—urinary bladder cancer	0.000142	0.00182	CbGeAlD
Gefitinib—Dehydration—Epirubicin—urinary bladder cancer	0.000141	0.00104	CcSEcCtD
Gefitinib—Skin disorder—Cisplatin—urinary bladder cancer	0.000141	0.00104	CcSEcCtD
Gefitinib—Dry skin—Epirubicin—urinary bladder cancer	0.000139	0.00103	CcSEcCtD
Gefitinib—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000139	0.00103	CcSEcCtD
Gefitinib—Anorexia—Cisplatin—urinary bladder cancer	0.000138	0.00102	CcSEcCtD
Gefitinib—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000138	0.00102	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000138	0.00102	CcSEcCtD
Gefitinib—Pancreatitis—Methotrexate—urinary bladder cancer	0.000137	0.00102	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000136	0.00101	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000136	0.00101	CcSEcCtD
Gefitinib—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000136	0.00101	CcSEcCtD
Gefitinib—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000136	0.00101	CcSEcCtD
Gefitinib—Hypotension—Cisplatin—urinary bladder cancer	0.000135	0.001	CcSEcCtD
Gefitinib—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000135	0.001	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000134	0.000995	CcSEcCtD
Gefitinib—Fatigue—Gemcitabine—urinary bladder cancer	0.000134	0.000994	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000134	0.00099	CcSEcCtD
Gefitinib—Pain—Gemcitabine—urinary bladder cancer	0.000133	0.000986	CcSEcCtD
Gefitinib—Constipation—Gemcitabine—urinary bladder cancer	0.000133	0.000986	CcSEcCtD
Gefitinib—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000133	0.000985	CcSEcCtD
Gefitinib—Asthenia—Thiotepa—urinary bladder cancer	0.000133	0.000983	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000132	0.000978	CcSEcCtD
Gefitinib—Infection—Etoposide—urinary bladder cancer	0.000132	0.000978	CcSEcCtD
Gefitinib—Pruritus—Thiotepa—urinary bladder cancer	0.000131	0.000969	CcSEcCtD
Gefitinib—Pain—Fluorouracil—urinary bladder cancer	0.000131	0.000969	CcSEcCtD
Gefitinib—Dehydration—Doxorubicin—urinary bladder cancer	0.00013	0.000966	CcSEcCtD
Gefitinib—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00013	0.000964	CcSEcCtD
Gefitinib—Dyspnoea—Cisplatin—urinary bladder cancer	0.000129	0.000958	CcSEcCtD
Gefitinib—Skin disorder—Etoposide—urinary bladder cancer	0.000129	0.000956	CcSEcCtD
Gefitinib—Dry skin—Doxorubicin—urinary bladder cancer	0.000128	0.000952	CcSEcCtD
Gefitinib—Pancreatitis—Epirubicin—urinary bladder cancer	0.000128	0.000951	CcSEcCtD
Gefitinib—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000128	0.000945	CcSEcCtD
Gefitinib—Anorexia—Etoposide—urinary bladder cancer	0.000127	0.000938	CcSEcCtD
Gefitinib—Diarrhoea—Thiotepa—urinary bladder cancer	0.000127	0.000937	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000126	0.000935	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000126	0.000935	CcSEcCtD
Gefitinib—Decreased appetite—Cisplatin—urinary bladder cancer	0.000126	0.000934	CcSEcCtD
Gefitinib—Pneumonia—Methotrexate—urinary bladder cancer	0.000125	0.00093	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000125	0.000927	CcSEcCtD
Gefitinib—Infestation NOS—Methotrexate—urinary bladder cancer	0.000125	0.000924	CcSEcCtD
Gefitinib—Infestation—Methotrexate—urinary bladder cancer	0.000125	0.000924	CcSEcCtD
Gefitinib—Hypotension—Etoposide—urinary bladder cancer	0.000124	0.00092	CcSEcCtD
Gefitinib—Pain—Cisplatin—urinary bladder cancer	0.000124	0.000919	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000124	0.000916	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000124	0.000916	CcSEcCtD
Gefitinib—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000123	0.000911	CcSEcCtD
Gefitinib—Stomatitis—Methotrexate—urinary bladder cancer	0.000122	0.000901	CcSEcCtD
Gefitinib—Urticaria—Fluorouracil—urinary bladder cancer	0.000122	0.0009	CcSEcCtD
Gefitinib—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000121	0.000898	CcSEcCtD
Gefitinib—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000121	0.000896	CcSEcCtD
Gefitinib—Haematuria—Methotrexate—urinary bladder cancer	0.000119	0.000881	CcSEcCtD
Gefitinib—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000119	0.00088	CcSEcCtD
Gefitinib—Weight decreased—Epirubicin—urinary bladder cancer	0.000118	0.000878	CcSEcCtD
Gefitinib—Dyspnoea—Etoposide—urinary bladder cancer	0.000118	0.000877	CcSEcCtD
Gefitinib—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000118	0.000874	CcSEcCtD
Gefitinib—Epistaxis—Methotrexate—urinary bladder cancer	0.000118	0.000872	CcSEcCtD
Gefitinib—Vomiting—Thiotepa—urinary bladder cancer	0.000118	0.000871	CcSEcCtD
Gefitinib—Pneumonia—Epirubicin—urinary bladder cancer	0.000117	0.00087	CcSEcCtD
Gefitinib—Infestation NOS—Epirubicin—urinary bladder cancer	0.000117	0.000865	CcSEcCtD
Gefitinib—Infestation—Epirubicin—urinary bladder cancer	0.000117	0.000865	CcSEcCtD
Gefitinib—Rash—Thiotepa—urinary bladder cancer	0.000117	0.000864	CcSEcCtD
Gefitinib—Dermatitis—Thiotepa—urinary bladder cancer	0.000116	0.000863	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000116	0.000858	CcSEcCtD
Gefitinib—Decreased appetite—Etoposide—urinary bladder cancer	0.000115	0.000856	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000115	0.00085	CcSEcCtD
Gefitinib—Body temperature increased—Cisplatin—urinary bladder cancer	0.000115	0.000849	CcSEcCtD
Gefitinib—Fatigue—Etoposide—urinary bladder cancer	0.000115	0.000849	CcSEcCtD
Gefitinib—Stomatitis—Epirubicin—urinary bladder cancer	0.000114	0.000843	CcSEcCtD
Gefitinib—Pain—Etoposide—urinary bladder cancer	0.000114	0.000842	CcSEcCtD
Gefitinib—Constipation—Etoposide—urinary bladder cancer	0.000114	0.000842	CcSEcCtD
Gefitinib—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000113	0.000841	CcSEcCtD
Gefitinib—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000113	0.000835	CcSEcCtD
Gefitinib—Haemoglobin—Methotrexate—urinary bladder cancer	0.000113	0.000834	CcSEcCtD
Gefitinib—Hepatitis—Methotrexate—urinary bladder cancer	0.000112	0.00083	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—urinary bladder cancer	0.000112	0.00083	CcSEcCtD
Gefitinib—Asthenia—Gemcitabine—urinary bladder cancer	0.000112	0.000827	CcSEcCtD
Gefitinib—Haematuria—Epirubicin—urinary bladder cancer	0.000111	0.000825	CcSEcCtD
Gefitinib—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000111	0.000819	CcSEcCtD
Gefitinib—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00011	0.000818	CcSEcCtD
Gefitinib—Epistaxis—Epirubicin—urinary bladder cancer	0.00011	0.000816	CcSEcCtD
Gefitinib—Pruritus—Gemcitabine—urinary bladder cancer	0.00011	0.000815	CcSEcCtD
Gefitinib—Nausea—Thiotepa—urinary bladder cancer	0.00011	0.000814	CcSEcCtD
Gefitinib—Urethral disorder—Methotrexate—urinary bladder cancer	0.00011	0.000813	CcSEcCtD
Gefitinib—Weight decreased—Doxorubicin—urinary bladder cancer	0.00011	0.000812	CcSEcCtD
Gefitinib—Pneumonia—Doxorubicin—urinary bladder cancer	0.000109	0.000805	CcSEcCtD
Gefitinib—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000109	0.000805	CcSEcCtD
Gefitinib—Pruritus—Fluorouracil—urinary bladder cancer	0.000108	0.000802	CcSEcCtD
Gefitinib—Infestation—Doxorubicin—urinary bladder cancer	0.000108	0.0008	CcSEcCtD
Gefitinib—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000108	0.0008	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000107	0.000793	CcSEcCtD
Gefitinib—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000107	0.000791	CcSEcCtD
Gefitinib—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000106	0.000789	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000106	0.000785	CcSEcCtD
Gefitinib—Urticaria—Etoposide—urinary bladder cancer	0.000106	0.000782	CcSEcCtD
Gefitinib—Haemoglobin—Epirubicin—urinary bladder cancer	0.000105	0.00078	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—urinary bladder cancer	0.000105	0.00078	CcSEcCtD
Gefitinib—Abdominal pain—Etoposide—urinary bladder cancer	0.000105	0.000778	CcSEcCtD
Gefitinib—Body temperature increased—Etoposide—urinary bladder cancer	0.000105	0.000778	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000105	0.000778	CcSEcCtD
Gefitinib—Hepatitis—Epirubicin—urinary bladder cancer	0.000105	0.000777	CcSEcCtD
Gefitinib—Haemorrhage—Epirubicin—urinary bladder cancer	0.000105	0.000777	CcSEcCtD
Gefitinib—Eye disorder—Methotrexate—urinary bladder cancer	0.000105	0.000775	CcSEcCtD
Gefitinib—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000105	0.000775	CcSEcCtD
Gefitinib—Asthenia—Cisplatin—urinary bladder cancer	0.000104	0.000771	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000104	0.00077	CcSEcCtD
Gefitinib—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000104	0.000767	CcSEcCtD
Gefitinib—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000103	0.000765	CcSEcCtD
Gefitinib—Haematuria—Doxorubicin—urinary bladder cancer	0.000103	0.000763	CcSEcCtD
Gefitinib—Urethral disorder—Epirubicin—urinary bladder cancer	0.000103	0.000761	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000102	0.000757	CcSEcCtD
Gefitinib—Epistaxis—Doxorubicin—urinary bladder cancer	0.000102	0.000755	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—urinary bladder cancer	0.000102	0.000753	CcSEcCtD
Gefitinib—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000101	0.000748	CcSEcCtD
Gefitinib—Diarrhoea—Cisplatin—urinary bladder cancer	9.92e-05	0.000735	CcSEcCtD
Gefitinib—Erythema multiforme—Epirubicin—urinary bladder cancer	9.91e-05	0.000734	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—urinary bladder cancer	9.9e-05	0.000733	CcSEcCtD
Gefitinib—Vomiting—Gemcitabine—urinary bladder cancer	9.89e-05	0.000733	CcSEcCtD
Gefitinib—Rash—Gemcitabine—urinary bladder cancer	9.81e-05	0.000727	CcSEcCtD
Gefitinib—Dermatitis—Gemcitabine—urinary bladder cancer	9.8e-05	0.000726	CcSEcCtD
Gefitinib—Eye disorder—Epirubicin—urinary bladder cancer	9.8e-05	0.000726	CcSEcCtD
Gefitinib—Hypersensitivity—Etoposide—urinary bladder cancer	9.79e-05	0.000725	CcSEcCtD
Gefitinib—Malnutrition—Methotrexate—urinary bladder cancer	9.75e-05	0.000722	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—urinary bladder cancer	9.75e-05	0.000722	CcSEcCtD
Gefitinib—Cardiac disorder—Epirubicin—urinary bladder cancer	9.73e-05	0.000721	CcSEcCtD
Gefitinib—Vomiting—Fluorouracil—urinary bladder cancer	9.73e-05	0.000721	CcSEcCtD
Gefitinib—Haemorrhage—Doxorubicin—urinary bladder cancer	9.7e-05	0.000718	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—urinary bladder cancer	9.7e-05	0.000718	CcSEcCtD
Gefitinib—Rash—Fluorouracil—urinary bladder cancer	9.64e-05	0.000715	CcSEcCtD
Gefitinib—Dermatitis—Fluorouracil—urinary bladder cancer	9.64e-05	0.000714	CcSEcCtD
Gefitinib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	9.58e-05	0.00071	CcSEcCtD
Gefitinib—Oedema peripheral—Doxorubicin—urinary bladder cancer	9.55e-05	0.000708	CcSEcCtD
Gefitinib—Asthenia—Etoposide—urinary bladder cancer	9.53e-05	0.000706	CcSEcCtD
Gefitinib—Angiopathy—Epirubicin—urinary bladder cancer	9.51e-05	0.000705	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—urinary bladder cancer	9.51e-05	0.000704	CcSEcCtD
Gefitinib—Mediastinal disorder—Epirubicin—urinary bladder cancer	9.45e-05	0.0007	CcSEcCtD
Gefitinib—Pruritus—Etoposide—urinary bladder cancer	9.4e-05	0.000696	CcSEcCtD
Gefitinib—Arrhythmia—Epirubicin—urinary bladder cancer	9.36e-05	0.000694	CcSEcCtD
Gefitinib—Alopecia—Epirubicin—urinary bladder cancer	9.26e-05	0.000686	CcSEcCtD
Gefitinib—Nausea—Gemcitabine—urinary bladder cancer	9.24e-05	0.000685	CcSEcCtD
Gefitinib—Vomiting—Cisplatin—urinary bladder cancer	9.22e-05	0.000683	CcSEcCtD
Gefitinib—Erythema multiforme—Doxorubicin—urinary bladder cancer	9.17e-05	0.000679	CcSEcCtD
Gefitinib—ABCB1—lymph node—urinary bladder cancer	9.16e-05	0.00118	CbGeAlD
Gefitinib—Rash—Cisplatin—urinary bladder cancer	9.14e-05	0.000677	CcSEcCtD
Gefitinib—Dermatitis—Cisplatin—urinary bladder cancer	9.13e-05	0.000677	CcSEcCtD
Gefitinib—Malnutrition—Epirubicin—urinary bladder cancer	9.12e-05	0.000676	CcSEcCtD
Gefitinib—Diarrhoea—Etoposide—urinary bladder cancer	9.09e-05	0.000673	CcSEcCtD
Gefitinib—Nausea—Fluorouracil—urinary bladder cancer	9.09e-05	0.000673	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—urinary bladder cancer	9.06e-05	0.000671	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—urinary bladder cancer	9.01e-05	0.000668	CcSEcCtD
Gefitinib—Cardiac disorder—Doxorubicin—urinary bladder cancer	9e-05	0.000667	CcSEcCtD
Gefitinib—Angiopathy—Doxorubicin—urinary bladder cancer	8.8e-05	0.000652	CcSEcCtD
Gefitinib—Malaise—Methotrexate—urinary bladder cancer	8.79e-05	0.000651	CcSEcCtD
Gefitinib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	8.74e-05	0.000648	CcSEcCtD
Gefitinib—Arrhythmia—Doxorubicin—urinary bladder cancer	8.66e-05	0.000642	CcSEcCtD
Gefitinib—Nausea—Cisplatin—urinary bladder cancer	8.61e-05	0.000638	CcSEcCtD
Gefitinib—Alopecia—Doxorubicin—urinary bladder cancer	8.57e-05	0.000635	CcSEcCtD
Gefitinib—Cough—Methotrexate—urinary bladder cancer	8.51e-05	0.00063	CcSEcCtD
Gefitinib—Vomiting—Etoposide—urinary bladder cancer	8.45e-05	0.000626	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—urinary bladder cancer	8.44e-05	0.000625	CcSEcCtD
Gefitinib—Anaemia—Epirubicin—urinary bladder cancer	8.43e-05	0.000625	CcSEcCtD
Gefitinib—Rash—Etoposide—urinary bladder cancer	8.38e-05	0.000621	CcSEcCtD
Gefitinib—Dermatitis—Etoposide—urinary bladder cancer	8.37e-05	0.00062	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	8.24e-05	0.000611	CcSEcCtD
Gefitinib—Malaise—Epirubicin—urinary bladder cancer	8.23e-05	0.00061	CcSEcCtD
Gefitinib—Cough—Epirubicin—urinary bladder cancer	7.96e-05	0.00059	CcSEcCtD
Gefitinib—Infection—Methotrexate—urinary bladder cancer	7.91e-05	0.000586	CcSEcCtD
Gefitinib—Nausea—Etoposide—urinary bladder cancer	7.89e-05	0.000585	CcSEcCtD
Gefitinib—Nervous system disorder—Methotrexate—urinary bladder cancer	7.8e-05	0.000578	CcSEcCtD
Gefitinib—Anaemia—Doxorubicin—urinary bladder cancer	7.8e-05	0.000578	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—urinary bladder cancer	7.79e-05	0.000577	CcSEcCtD
Gefitinib—Skin disorder—Methotrexate—urinary bladder cancer	7.73e-05	0.000573	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	7.71e-05	0.000572	CcSEcCtD
Gefitinib—Malaise—Doxorubicin—urinary bladder cancer	7.61e-05	0.000564	CcSEcCtD
Gefitinib—Dry mouth—Epirubicin—urinary bladder cancer	7.6e-05	0.000563	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—urinary bladder cancer	7.58e-05	0.000562	CcSEcCtD
Gefitinib—Hypotension—Methotrexate—urinary bladder cancer	7.44e-05	0.000551	CcSEcCtD
Gefitinib—Infection—Epirubicin—urinary bladder cancer	7.4e-05	0.000548	CcSEcCtD
Gefitinib—Cough—Doxorubicin—urinary bladder cancer	7.37e-05	0.000546	CcSEcCtD
Gefitinib—Shock—Epirubicin—urinary bladder cancer	7.33e-05	0.000543	CcSEcCtD
Gefitinib—Nervous system disorder—Epirubicin—urinary bladder cancer	7.3e-05	0.000541	CcSEcCtD
Gefitinib—Thrombocytopenia—Epirubicin—urinary bladder cancer	7.29e-05	0.00054	CcSEcCtD
Gefitinib—Skin disorder—Epirubicin—urinary bladder cancer	7.23e-05	0.000536	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	7.14e-05	0.000529	CcSEcCtD
Gefitinib—Anorexia—Epirubicin—urinary bladder cancer	7.1e-05	0.000526	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—urinary bladder cancer	7.09e-05	0.000526	CcSEcCtD
Gefitinib—Dry mouth—Doxorubicin—urinary bladder cancer	7.03e-05	0.000521	CcSEcCtD
Gefitinib—Hypotension—Epirubicin—urinary bladder cancer	6.96e-05	0.000516	CcSEcCtD
Gefitinib—Decreased appetite—Methotrexate—urinary bladder cancer	6.92e-05	0.000512	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	6.87e-05	0.000509	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—urinary bladder cancer	6.86e-05	0.000508	CcSEcCtD
Gefitinib—Infection—Doxorubicin—urinary bladder cancer	6.85e-05	0.000507	CcSEcCtD
Gefitinib—Pain—Methotrexate—urinary bladder cancer	6.8e-05	0.000504	CcSEcCtD
Gefitinib—Shock—Doxorubicin—urinary bladder cancer	6.78e-05	0.000502	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—urinary bladder cancer	6.76e-05	0.000501	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.75e-05	0.0005	CcSEcCtD
Gefitinib—Skin disorder—Doxorubicin—urinary bladder cancer	6.69e-05	0.000496	CcSEcCtD
Gefitinib—Dyspnoea—Epirubicin—urinary bladder cancer	6.64e-05	0.000492	CcSEcCtD
Gefitinib—Anorexia—Doxorubicin—urinary bladder cancer	6.57e-05	0.000487	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	6.51e-05	0.000482	CcSEcCtD
Gefitinib—Decreased appetite—Epirubicin—urinary bladder cancer	6.47e-05	0.00048	CcSEcCtD
Gefitinib—Hypotension—Doxorubicin—urinary bladder cancer	6.44e-05	0.000477	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.43e-05	0.000476	CcSEcCtD
Gefitinib—Fatigue—Epirubicin—urinary bladder cancer	6.42e-05	0.000476	CcSEcCtD
Gefitinib—Pain—Epirubicin—urinary bladder cancer	6.37e-05	0.000472	CcSEcCtD
Gefitinib—Constipation—Epirubicin—urinary bladder cancer	6.37e-05	0.000472	CcSEcCtD
Gefitinib—Urticaria—Methotrexate—urinary bladder cancer	6.32e-05	0.000468	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—urinary bladder cancer	6.29e-05	0.000466	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—urinary bladder cancer	6.29e-05	0.000466	CcSEcCtD
Gefitinib—Dyspnoea—Doxorubicin—urinary bladder cancer	6.14e-05	0.000455	CcSEcCtD
Gefitinib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	6.09e-05	0.000451	CcSEcCtD
Gefitinib—Decreased appetite—Doxorubicin—urinary bladder cancer	5.99e-05	0.000444	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	5.95e-05	0.000441	CcSEcCtD
Gefitinib—Fatigue—Doxorubicin—urinary bladder cancer	5.94e-05	0.00044	CcSEcCtD
Gefitinib—Urticaria—Epirubicin—urinary bladder cancer	5.92e-05	0.000438	CcSEcCtD
Gefitinib—Pain—Doxorubicin—urinary bladder cancer	5.89e-05	0.000437	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—urinary bladder cancer	5.89e-05	0.000437	CcSEcCtD
Gefitinib—Body temperature increased—Epirubicin—urinary bladder cancer	5.89e-05	0.000436	CcSEcCtD
Gefitinib—Abdominal pain—Epirubicin—urinary bladder cancer	5.89e-05	0.000436	CcSEcCtD
Gefitinib—Hypersensitivity—Methotrexate—urinary bladder cancer	5.86e-05	0.000434	CcSEcCtD
Gefitinib—Asthenia—Methotrexate—urinary bladder cancer	5.71e-05	0.000423	CcSEcCtD
Gefitinib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.63e-05	0.000417	CcSEcCtD
Gefitinib—Pruritus—Methotrexate—urinary bladder cancer	5.63e-05	0.000417	CcSEcCtD
Gefitinib—Hypersensitivity—Epirubicin—urinary bladder cancer	5.49e-05	0.000406	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—urinary bladder cancer	5.47e-05	0.000406	CcSEcCtD
Gefitinib—Abdominal pain—Doxorubicin—urinary bladder cancer	5.45e-05	0.000404	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—urinary bladder cancer	5.45e-05	0.000404	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—urinary bladder cancer	5.44e-05	0.000403	CcSEcCtD
Gefitinib—Asthenia—Epirubicin—urinary bladder cancer	5.34e-05	0.000396	CcSEcCtD
Gefitinib—Pruritus—Epirubicin—urinary bladder cancer	5.27e-05	0.00039	CcSEcCtD
Gefitinib—Diarrhoea—Epirubicin—urinary bladder cancer	5.1e-05	0.000377	CcSEcCtD
Gefitinib—Hypersensitivity—Doxorubicin—urinary bladder cancer	5.08e-05	0.000376	CcSEcCtD
Gefitinib—Vomiting—Methotrexate—urinary bladder cancer	5.06e-05	0.000375	CcSEcCtD
Gefitinib—Rash—Methotrexate—urinary bladder cancer	5.02e-05	0.000372	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—urinary bladder cancer	5.01e-05	0.000371	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—urinary bladder cancer	4.94e-05	0.000366	CcSEcCtD
Gefitinib—Pruritus—Doxorubicin—urinary bladder cancer	4.87e-05	0.000361	CcSEcCtD
Gefitinib—Vomiting—Epirubicin—urinary bladder cancer	4.73e-05	0.000351	CcSEcCtD
Gefitinib—Nausea—Methotrexate—urinary bladder cancer	4.73e-05	0.00035	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—urinary bladder cancer	4.71e-05	0.000349	CcSEcCtD
Gefitinib—Rash—Epirubicin—urinary bladder cancer	4.7e-05	0.000348	CcSEcCtD
Gefitinib—Dermatitis—Epirubicin—urinary bladder cancer	4.69e-05	0.000348	CcSEcCtD
Gefitinib—Nausea—Epirubicin—urinary bladder cancer	4.42e-05	0.000328	CcSEcCtD
Gefitinib—Vomiting—Doxorubicin—urinary bladder cancer	4.38e-05	0.000325	CcSEcCtD
Gefitinib—Rash—Doxorubicin—urinary bladder cancer	4.34e-05	0.000322	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—urinary bladder cancer	4.34e-05	0.000322	CcSEcCtD
Gefitinib—Nausea—Doxorubicin—urinary bladder cancer	4.09e-05	0.000303	CcSEcCtD
Gefitinib—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	5.96e-06	4.44e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NCOR1—urinary bladder cancer	5.95e-06	4.43e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.92e-06	4.41e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—RRM2—urinary bladder cancer	5.92e-06	4.41e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—MTHFR—urinary bladder cancer	5.87e-06	4.38e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NQO1—urinary bladder cancer	5.87e-06	4.37e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—RRM2—urinary bladder cancer	5.87e-06	4.37e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CREBBP—urinary bladder cancer	5.85e-06	4.36e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CXCL8—urinary bladder cancer	5.84e-06	4.35e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—HPGDS—urinary bladder cancer	5.81e-06	4.33e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ENO2—urinary bladder cancer	5.81e-06	4.33e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL2—urinary bladder cancer	5.8e-06	4.32e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—HRAS—urinary bladder cancer	5.79e-06	4.31e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	5.78e-06	4.31e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—KRAS—urinary bladder cancer	5.76e-06	4.29e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—HRAS—urinary bladder cancer	5.74e-06	4.28e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MYC—urinary bladder cancer	5.73e-06	4.27e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—KRAS—urinary bladder cancer	5.73e-06	4.27e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.69e-06	4.24e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.69e-06	4.24e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCND1—urinary bladder cancer	5.65e-06	4.21e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTT1—urinary bladder cancer	5.64e-06	4.2e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EGFR—urinary bladder cancer	5.61e-06	4.18e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL2—urinary bladder cancer	5.59e-06	4.16e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—RHOA—urinary bladder cancer	5.54e-06	4.13e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CXCL8—urinary bladder cancer	5.51e-06	4.1e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EGFR—urinary bladder cancer	5.5e-06	4.1e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MMP9—urinary bladder cancer	5.48e-06	4.09e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ENO2—urinary bladder cancer	5.48e-06	4.08e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	5.48e-06	4.08e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CDKN1A—urinary bladder cancer	5.47e-06	4.07e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—PTEN—urinary bladder cancer	5.45e-06	4.06e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCND1—urinary bladder cancer	5.45e-06	4.06e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	5.43e-06	4.05e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ENO2—urinary bladder cancer	5.43e-06	4.05e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.4e-06	4.02e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NQO1—urinary bladder cancer	5.35e-06	3.99e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	5.31e-06	3.96e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ERBB2—urinary bladder cancer	5.31e-06	3.95e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HRAS—urinary bladder cancer	5.31e-06	3.95e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—KRAS—urinary bladder cancer	5.3e-06	3.95e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—RHOA—urinary bladder cancer	5.29e-06	3.94e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MMP9—urinary bladder cancer	5.29e-06	3.94e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IL2—urinary bladder cancer	5.28e-06	3.94e-05	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.28e-06	3.93e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	5.27e-06	3.93e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CDKN1A—urinary bladder cancer	5.27e-06	3.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL2—urinary bladder cancer	5.26e-06	3.92e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PTEN—urinary bladder cancer	5.26e-06	3.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TERT—urinary bladder cancer	5.24e-06	3.91e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EP300—urinary bladder cancer	5.2e-06	3.87e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KRAS—urinary bladder cancer	5.2e-06	3.87e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.19e-06	3.87e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.19e-06	3.87e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	5.18e-06	3.86e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ERBB2—urinary bladder cancer	5.13e-06	3.82e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HRAS—urinary bladder cancer	5.07e-06	3.78e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—SRC—urinary bladder cancer	5.06e-06	3.77e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EP300—urinary bladder cancer	5.01e-06	3.73e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.97e-06	3.7e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.96e-06	3.69e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—ERBB2—urinary bladder cancer	4.9e-06	3.65e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HRAS—urinary bladder cancer	4.9e-06	3.65e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	4.89e-06	3.65e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—SRC—urinary bladder cancer	4.87e-06	3.63e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HRAS—urinary bladder cancer	4.87e-06	3.63e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CXCL8—urinary bladder cancer	4.87e-06	3.63e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—TYMS—urinary bladder cancer	4.82e-06	3.59e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FGFR3—urinary bladder cancer	4.81e-06	3.59e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL2—urinary bladder cancer	4.81e-06	3.58e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NQO1—urinary bladder cancer	4.8e-06	3.58e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—urinary bladder cancer	4.79e-06	3.57e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PPARG—urinary bladder cancer	4.76e-06	3.55e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	4.76e-06	3.55e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	4.76e-06	3.55e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—EP300—urinary bladder cancer	4.74e-06	3.53e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.74e-06	3.53e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—urinary bladder cancer	4.71e-06	3.51e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NQO1—urinary bladder cancer	4.69e-06	3.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ESR1—urinary bladder cancer	4.67e-06	3.48e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.66e-06	3.47e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL2—urinary bladder cancer	4.65e-06	3.46e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—SRC—urinary bladder cancer	4.61e-06	3.44e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CREBBP—urinary bladder cancer	4.57e-06	3.41e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GPX1—urinary bladder cancer	4.56e-06	3.4e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—TYMS—urinary bladder cancer	4.55e-06	3.39e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CDKN1A—urinary bladder cancer	4.54e-06	3.38e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCND1—urinary bladder cancer	4.53e-06	3.38e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MYC—urinary bladder cancer	4.53e-06	3.38e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.53e-06	3.37e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PTEN—urinary bladder cancer	4.53e-06	3.37e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HRAS—urinary bladder cancer	4.5e-06	3.35e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	4.5e-06	3.35e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	4.5e-06	3.35e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.48e-06	3.34e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	4.48e-06	3.33e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTP1—urinary bladder cancer	4.46e-06	3.32e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EGFR—urinary bladder cancer	4.43e-06	3.3e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HRAS—urinary bladder cancer	4.42e-06	3.29e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NQO1—urinary bladder cancer	4.42e-06	3.29e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—urinary bladder cancer	4.4e-06	3.28e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CDKN1A—urinary bladder cancer	4.39e-06	3.27e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NQO1—urinary bladder cancer	4.38e-06	3.26e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PTEN—urinary bladder cancer	4.38e-06	3.26e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MYC—urinary bladder cancer	4.37e-06	3.25e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.32e-06	3.22e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—EP300—urinary bladder cancer	4.32e-06	3.22e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GPX1—urinary bladder cancer	4.31e-06	3.21e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—urinary bladder cancer	4.27e-06	3.18e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.25e-06	3.17e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	4.23e-06	3.15e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	4.21e-06	3.13e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—SRC—urinary bladder cancer	4.2e-06	3.13e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CDKN1A—urinary bladder cancer	4.19e-06	3.12e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KRAS—urinary bladder cancer	4.19e-06	3.12e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTEN—urinary bladder cancer	4.18e-06	3.11e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EP300—urinary bladder cancer	4.17e-06	3.11e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TYMS—urinary bladder cancer	4.15e-06	3.09e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NCOR1—urinary bladder cancer	4.1e-06	3.05e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTM1—urinary bladder cancer	4.1e-06	3.05e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CREBBP—urinary bladder cancer	4.1e-06	3.05e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.06e-06	3.03e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SRC—urinary bladder cancer	4.06e-06	3.02e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IGF1—urinary bladder cancer	4.05e-06	3.01e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KRAS—urinary bladder cancer	4.04e-06	3.01e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	4.01e-06	2.98e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—EP300—urinary bladder cancer	3.98e-06	2.97e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	3.97e-06	2.96e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GPX1—urinary bladder cancer	3.93e-06	2.93e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTP1—urinary bladder cancer	3.91e-06	2.91e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.88e-06	2.89e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—SRC—urinary bladder cancer	3.87e-06	2.89e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.87e-06	2.88e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ERCC2—urinary bladder cancer	3.85e-06	2.87e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—urinary bladder cancer	3.82e-06	2.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—urinary bladder cancer	3.8e-06	2.83e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—urinary bladder cancer	3.75e-06	2.79e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TYMS—urinary bladder cancer	3.72e-06	2.77e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—urinary bladder cancer	3.72e-06	2.77e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RHOA—urinary bladder cancer	3.71e-06	2.76e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.7e-06	2.76e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	3.68e-06	2.74e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	3.68e-06	2.74e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	3.68e-06	2.74e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	3.65e-06	2.72e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—urinary bladder cancer	3.64e-06	2.71e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TYMS—urinary bladder cancer	3.63e-06	2.71e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MTHFR—urinary bladder cancer	3.62e-06	2.7e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NCOR1—urinary bladder cancer	3.59e-06	2.68e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTM1—urinary bladder cancer	3.59e-06	2.68e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—urinary bladder cancer	3.59e-06	2.67e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.58e-06	2.67e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.58e-06	2.67e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—urinary bladder cancer	3.56e-06	2.65e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—urinary bladder cancer	3.56e-06	2.65e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.53e-06	2.63e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GPX1—urinary bladder cancer	3.52e-06	2.63e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—urinary bladder cancer	3.48e-06	2.59e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.47e-06	2.59e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—urinary bladder cancer	3.47e-06	2.59e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	3.46e-06	2.58e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GPX1—urinary bladder cancer	3.44e-06	2.56e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ERBB2—urinary bladder cancer	3.43e-06	2.56e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—urinary bladder cancer	3.43e-06	2.56e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TYMS—urinary bladder cancer	3.42e-06	2.55e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PPARG—urinary bladder cancer	3.41e-06	2.54e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TYMS—urinary bladder cancer	3.4e-06	2.53e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—urinary bladder cancer	3.39e-06	2.53e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	3.39e-06	2.52e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	3.39e-06	2.52e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ERCC2—urinary bladder cancer	3.38e-06	2.52e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—urinary bladder cancer	3.36e-06	2.5e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	3.36e-06	2.5e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	3.36e-06	2.5e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	3.28e-06	2.44e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTEN—urinary bladder cancer	3.27e-06	2.43e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCL8—urinary bladder cancer	3.25e-06	2.42e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	3.25e-06	2.42e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—urinary bladder cancer	3.25e-06	2.42e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GPX1—urinary bladder cancer	3.24e-06	2.42e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—urinary bladder cancer	3.23e-06	2.41e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPARG—urinary bladder cancer	3.22e-06	2.4e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GPX1—urinary bladder cancer	3.21e-06	2.39e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—urinary bladder cancer	3.21e-06	2.39e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	3.18e-06	2.37e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MTHFR—urinary bladder cancer	3.17e-06	2.37e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	3.16e-06	2.35e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—EP300—urinary bladder cancer	3.12e-06	2.32e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2—urinary bladder cancer	3.11e-06	2.32e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	3.1e-06	2.31e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—urinary bladder cancer	3.03e-06	2.26e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.99e-06	2.23e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—urinary bladder cancer	2.99e-06	2.22e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.97e-06	2.21e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—urinary bladder cancer	2.95e-06	2.2e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—urinary bladder cancer	2.94e-06	2.19e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPARG—urinary bladder cancer	2.94e-06	2.19e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CDKN1A—urinary bladder cancer	2.93e-06	2.18e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PTEN—urinary bladder cancer	2.93e-06	2.18e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.89e-06	2.15e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—urinary bladder cancer	2.86e-06	2.13e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CREBBP—urinary bladder cancer	2.82e-06	2.1e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—EP300—urinary bladder cancer	2.79e-06	2.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—urinary bladder cancer	2.73e-06	2.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SRC—urinary bladder cancer	2.71e-06	2.02e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	2.68e-06	2e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARG—urinary bladder cancer	2.64e-06	1.97e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARG—urinary bladder cancer	2.57e-06	1.92e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	2.54e-06	1.89e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	2.53e-06	1.89e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CREBBP—urinary bladder cancer	2.47e-06	1.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—urinary bladder cancer	2.43e-06	1.81e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.43e-06	1.81e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.41e-06	1.79e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.41e-06	1.79e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTEN—urinary bladder cancer	2.34e-06	1.74e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.33e-06	1.74e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—urinary bladder cancer	2.31e-06	1.72e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.31e-06	1.72e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—urinary bladder cancer	2.25e-06	1.67e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.24e-06	1.67e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—EP300—urinary bladder cancer	2.23e-06	1.66e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.21e-06	1.65e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.21e-06	1.65e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTEN—urinary bladder cancer	2.21e-06	1.65e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.12e-06	1.58e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—EP300—urinary bladder cancer	2.11e-06	1.57e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.08e-06	1.55e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	2.07e-06	1.55e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.03e-06	1.51e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTEN—urinary bladder cancer	2.02e-06	1.5e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—urinary bladder cancer	2e-06	1.49e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.96e-06	1.46e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—EP300—urinary bladder cancer	1.92e-06	1.43e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—urinary bladder cancer	1.91e-06	1.42e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.91e-06	1.42e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.89e-06	1.41e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.81e-06	1.35e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.77e-06	1.32e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.73e-06	1.29e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—EP300—urinary bladder cancer	1.68e-06	1.25e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.66e-06	1.24e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.65e-06	1.23e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.59e-06	1.18e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.59e-06	1.18e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.57e-06	1.17e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.52e-06	1.14e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.25e-06	9.3e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.09e-06	8.11e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.04e-06	7.73e-06	CbGpPWpGaD
